facebook
spears_logo

Top Recommended
Click to explore ranking

tatler_logo

Featured in
The Tatler Address Book

doctify_logo

Outstanding
Click to see reviews

spears_logo
tatler_logo
doctify_logo

What Happens if a Premium IOL Is Not Well Tolerated and How It Is Managed

1 min read

Most patients tolerate premium IOLs well. A minority do not, and the management pathway for those patients is what distinguishes a properly run premium IOL service from one that selects easy cases and hopes for the best.

The Intolerance Pathway

Persistent dysphotopsia, neuroadaptation failure, or dissatisfaction beyond 6-12 months are managed in three sequential steps. First, optimise modifiable variables: ocular surface disease, residual refractive error, and posterior capsular opacification. In a meaningful proportion of dissatisfied patients, optimisation alone resolves the complaint.¹

Step Two: Laser Enhancement

Residual refractive error is the most common, and most underestimated, cause of premium IOL dissatisfaction. Excimer laser enhancement (LASIK, PRK, or transPRK) on the corneal surface can address residual sphere and astigmatism within enhancement criteria.² For patients within those criteria, this resolves the great majority of complaints attributed to the lens itself.

Step Three: IOL Exchange

When optimisation and enhancement fail, IOL exchange is the definitive intervention. Removing the multifocal IOL and implanting a monofocal in its place reverses the optical strategy and resolves dysphotopsia in the substantial majority of patients.³ Exchange is more complex than primary surgery, with capsular bag scarring, zonular stress, and increased operative time as real considerations, but it is well-described, safe in experienced hands, and reliably effective.

The Clinical Position

A premium IOL service must include a clear pathway for the patient who does not adapt. Without one, dissatisfaction becomes regret, and the original surgeon is rarely the one who manages it.

References

  1. Galor A, Gonzalez M, Goldman D, O’Brien TP. Intraocular lens exchange surgery in dissatisfied patients with refractive intraocular lenses. J Cataract Refract Surg. 2009;35(10):1706-1710.
  2. Schallhorn SC, Hettinger KA, Pelouskova M, Teenan D, Venter JA, Hannan SJ, Schallhorn JM. Effect of residual astigmatism on uncorrected visual acuity and patient satisfaction in pseudophakic patients. J Cataract Refract Surg. 2021;47(8):991-998.
  3. Mamalis N, Brubaker J, Davis D, Espandar L, Werner L. Complications of foldable intraocular lenses requiring explantation or secondary intervention, 2007 survey update. J Cataract Refract Surg. 2008;34(9):1584-1591.

Related Topics

Return to Knowledge Base

About Blue Fin Vision®

Blue Fin Vision® is a GMC-registered, consultant-led ophthalmology clinic with CQC-regulated facilities across London, Hertfordshire, and Essex. Patient outcomes are independently audited by the National Ophthalmology Database, confirming exceptionally low complication rates.